LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 4 of 15: Mean cell count and mean growth rate across biological replicate 1. - Dataset (ID:20240)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | Canertinib | 3.33 | uM | LJP6 | 72 | hr | 868 | 2305 | 3486 | 0.6611 | 0.5488 |
MDA-MB-231 | Celastrol | 3.33 | uM | LJP6 | 72 | hr | 868 | 692 | 3486 | 0.1986 | -0.0671 |
MDA-MB-231 | CGP60474 | 3.33 | uM | LJP5 | 72 | hr | 868 | 631 | 3486 | 0.1812 | -0.0903 |
MDA-MB-231 | CGP60474 | 3.33 | uM | LJP6 | 72 | hr | 868 | 527 | 3486 | 0.1512 | -0.1303 |
MDA-MB-231 | CHIR-99021 | 3.33 | uM | LJP6 | 72 | hr | 868 | 2911 | 3486 | 0.8352 | 0.7805 |
MDA-MB-231 | CP724714 | 3.33 | uM | LJP5 | 72 | hr | 868 | 2362 | 3486 | 0.6777 | 0.5708 |
MDA-MB-231 | CP466722 | 3.33 | uM | LJP5 | 72 | hr | 868 | 3398 | 3486 | 0.9747 | 0.9664 |
MDA-MB-231 | Crizotinib | 3.33 | uM | LJP5 | 72 | hr | 868 | 1133 | 3486 | 0.3251 | 0.1013 |
MDA-MB-231 | Momelotinib | 3.33 | uM | LJP5 | 72 | hr | 868 | 2047 | 3486 | 0.5872 | 0.4504 |
MDA-MB-231 | Dasatinib | 3.33 | uM | LJP5 | 72 | hr | 868 | 515 | 3486 | 0.1477 | -0.1349 |
MDA-MB-231 | Dasatinib | 3.33 | uM | LJP6 | 72 | hr | 868 | 460 | 3486 | 0.1320 | -0.1558 |
MDA-MB-231 | Dovitinib | 3.33 | uM | LJP5 | 72 | hr | 868 | 1649 | 3486 | 0.4731 | 0.2984 |
MDA-MB-231 | Enzastaurin | 3.33 | uM | LJP5 | 72 | hr | 868 | 3483 | 3486 | 0.9990 | 0.9987 |
MDA-MB-231 | Erlotinib | 3.33 | uM | LJP5 | 72 | hr | 868 | 3356 | 3486 | 0.9626 | 0.9502 |
MDA-MB-231 | Foretinib | 3.33 | uM | LJP5 | 72 | hr | 868 | 1389 | 3486 | 0.3984 | 0.1989 |
MDA-MB-231 | R406 | 3.33 | uM | LJP6 | 72 | hr | 868 | 2438 | 3486 | 0.6995 | 0.5998 |
MDA-MB-231 | Pictilisib | 3.33 | uM | LJP6 | 72 | hr | 868 | 2550 | 3486 | 0.7316 | 0.6426 |
MDA-MB-231 | Gefitinib | 3.33 | uM | LJP6 | 72 | hr | 868 | 3848 | 3486 | 1.1037 | 1.1381 |
MDA-MB-231 | Geldanamycin | 3.33 | uM | LJP5 | 72 | hr | 868 | 859 | 3486 | 0.2465 | -0.0034 |
MDA-MB-231 | Geldanamycin | 3.33 | uM | LJP6 | 72 | hr | 868 | 964 | 3486 | 0.2766 | 0.0367 |
MDA-MB-231 | GSK1059615 | 3.33 | uM | LJP5 | 72 | hr | 868 | 781 | 3486 | 0.2240 | -0.0333 |
MDA-MB-231 | GSK1059615 | 3.33 | uM | LJP6 | 72 | hr | 868 | 1178 | 3486 | 0.3381 | 0.1186 |
MDA-MB-231 | GSK1904529A | 3.33 | uM | LJP6 | 72 | hr | 868 | 3396 | 3486 | 0.9742 | 0.9656 |
MDA-MB-231 | Omipalisib | 3.33 | uM | LJP6 | 72 | hr | 868 | 1030 | 3486 | 0.2954 | 0.0618 |
MDA-MB-231 | GSK 690693 | 3.33 | uM | LJP5 | 72 | hr | 868 | 3459 | 3486 | 0.9923 | 0.9898 |